ESCO2 (Establishment Of Sister Chromatid Cohesion N-Acetyltransferase 2)

The prolif Tex-based prognostic model demonstrates strong prognostic value and validated hub genes offer potential biomarkers and therapeutic targets. Our findings underscore the potential of prolif Tex cells as a biomarker and therapeutic target in ESCC.

Given its essential role in tumorigenesis, ESCO2 has increasingly been explored as a promising therapeutic target in recent years. This review article summarizes recent research progress regarding ESCO2 in malignant tumors, aiming to identify a novel target for their treatment.

In vivo experiments using xenograft mouse models consistently showed that ESCO2 silencing significantly inhibited tumor growth, increased apoptosis and necrosis, and reduced metastasis. Collectively, our findings establish ESCO2 as a novel oncogene driving breast cancer progression through PI3K/AKT/mTOR pathway activation, highlighting its potential as a promising therapeutic target for breast cancer intervention.

Our findings reveal that ESCO2 is upregulated in breast cancer and may contribute to cell cycle regulation and apoptosis through the p53-CDK1 and BAX/Bcl-2-caspase pathways. These results highlight ESCO2 as a potential therapeutic target and provide new mechanistic insights into breast cancer progression.

Most importantly, ESCO2 stimulated the PI3K/AKT/mTOR pathway, which ultimately accelerated the cell cycle and inhibited apoptosis, promoting HCC progression. The present study elucidated the mechanism by which ESCO2 regulates HCC proliferation: ESCO2 promotes HCC proliferation by accelerating the cell cycle and inhibiting apoptosis via the PI3K/AKT/mTOR signaling pathway.

Conclusion ESCO2 participates in regulating the immune infiltration and affecting the prognosis of patients in many cancers, especially in BLCA. ESCO2 may serve as a prognostic and immunotherapy biomarker in future treatment of human cancer.

Our results identify a posttranslational modification of ALKBH5 and its role in regulating antiviral innate immune responses through m6A modification. The finding provides an understanding of innate immunity and offers a potential therapeutic target for HSV-1, KSHV, and MPXV infections.

In conclusion, ESCO2 is a possible pan-cancer biomarker and oncogene that can reliably predict the prognosis of cancer patients. ESCO2 was also implicated in the cell cycle and proliferation regulation. In a nutshell, ESCO2 is a therapeutically viable and dependable target.

These findings suggest that ESCO2 is crucial in promoting HPC malignant progression through the STAT1 pathway and provides novel therapeutic targets for HPC treatment.

Mechanistically, circMETTL15 acts as a ceRNA for miR-374a-5p to regulate ESCO2 expression, thereby promoting the biological behavior of LoVo cells. In conclusion, the results of this study reveal the role of circMETTL15 in CRC and the underlying molecular mechanism, which provides potential data support for the development of future CRC drugs.